Neurocrine Biosciences (NBIX) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Bio-Techne (TECH) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 22.5% versus a gain of 4.7%. Over five years, NBIX leads with a +37.2% price change compared with -41.7% for TECH. Neurocrine Biosciences is the larger company by market cap ($14.58 billion vs $11.37 billion), about 1.3 times the size.
On valuation, Neurocrine Biosciences trades at a lower forward P/E (12.1x vs 31.4x for Bio-Techne). Bio-Techne pays a dividend yielding 0.44%, while Neurocrine Biosciences does not currently pay one. Neurocrine Biosciences converts more of its revenue into profit, with a net margin of 16.7% versus 15.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NBIX | TECH |
|---|---|---|
| Share price | $143.47 | $72.53 |
| Market cap | $14.58B | $11.37B |
| 1-day change | -1.40% | +0.14% |
| YTD return | +1.16% | +23.33% |
| 1-year return | +4.72% | +22.54% |
| 5-year return | +37.24% | -41.75% |
| P/E ratio (TTM) | 21.04 | 62.53 |
| Forward P/E | 12.08 | 31.36 |
| EPS (TTM) | $6.82 | $1.16 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | $2.86B | $1.22B |
| Revenue growth (YoY) | +21.45% | -0.38% |
| Net income (latest FY) | $478.60M | $181.86M |
| Gross margin | 98.18% | 65.77% |
| Operating margin | 21.64% | 20.73% |
| Net margin | 16.73% | 14.97% |
| 52-week high | $186.12 | $72.69 |
| 52-week low | $122.14 | $43.20 |
| Distance from 52-week high | -22.92% | -0.22% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +44.48% | -2.80% |
| Average volume | 1.30M | 3.12M |
| Shares outstanding | 101.65M | 156.82M |
| Employees | 2,500 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TECH has outperformed NBIX by 17.8 percentage points over the past year.
- Bio-Techne trades at a higher earnings multiple (62.5x vs 21.0x trailing P/E).
- Neurocrine Biosciences grew revenue faster in its latest fiscal year (+21.45% vs -0.38%).
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
NBIX vs TECH FAQ
Which is bigger, Neurocrine Biosciences or Bio-Techne?
Neurocrine Biosciences (NBIX) is larger, with a market capitalization of $14.58B compared with $11.37B for Bio-Techne (TECH).
Which stock has performed better over the past year, NBIX or TECH?
TECH returned +22.54% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, NBIX or TECH?
NBIX has the lower trailing P/E at 21.0, versus 62.5 for TECH. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Neurocrine Biosciences or Bio-Techne?
Bio-Techne pays a dividend yielding 0.44%, while Neurocrine Biosciences does not currently pay a regular dividend.
Are Neurocrine Biosciences and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.